OECI launches A&D Manual v4.0 – Setting the highest bar for quality in cancer care, research and education
The OECI is proud to announce the launch of Version 4.0 of the Accreditation and Designation User Manual, including the most comprehensive revision of our Quality Standards and Quantitative Data Measures to date. These standards are designed for cancer centres and networks across Europe and worldwide, and they continue to position the OECI A&D Programme as a leading cancer accreditation programme. Recognised by the International Society for Quality in Healthcare (ISQua), the OECI A&D Programme remains unique: it is voluntary, comprehensive, and integrates care, research, and education. With members in almost every European country, our network reflects a truly pan-European and global consensus on cancer care excellence.
A&D Manual v4.0 – Built on collaboration
This milestone is the result of close collaboration among the A&D Programme, OECI Members, our dedicated auditors, and external experts from leading European cancer organisations such as ESMO, ESTRO, ESSO, EORTC, EONS, EACS, ECO, Deutsche Krebshilfe, and Cancer Core Europe. Equally important, patient voices—represented by European Cancer Leagues and the OECI for Patients Working Group—have been integral in ensuring a strong focus on patient-centred care.
What’s new in the A&D Manual v4.0:
- Introduction of Core Standards and Core Essential Standards—critical requirements for certification.
- New standards on AI, theranostics, cancer networks, molecular diagnostics, prevention, surgical oncology, radiotherapy, pathology, survivorship, palliative and supportive care.
- Quality Standards tailored for Comprehensive Cancer Networks, supporting the goals of Europe’s Beating Cancer Plan.
The new standards apply to all cancer centres/networks entering the Programme after 1 July 2025.
By embracing Manual v4.0, cancer centres and networks will not only meet the highest international standards but also strengthen their role in delivering integrated, patient-centred cancer care. Together, we can continue to improve cancer outcomes for patients—across Europe and beyond.
